Document Detail

Assessment of anthracycline-induced cardiotoxicity with biochemical markers.
MedLine Citation:
PMID:  18199989     Owner:  NLM     Status:  MEDLINE    
AIM: Assessment of acute and chronic cardiotoxicity of anthracyclines in patients treated for acute leukemia (AL) with biochemical markers - "N-terminal pro brain natriuretic peptide" (NT-proBNP), cardiac troponin T (cTnT), creatine kinase MB (CK-MB mass), and echocardiography. METHODS: Twenty-six adult AL patients (mean age 46.2 +/- 12.4 years, 15 males) treated with 2-6 cycles of chemotherapy (CT) containing anthracyclines in the total cumulative dose of 464.3 +/- 117.5 mg/m2 were studied. Cardiac evaluation was performed at baseline, after first and last CT with anthracyclines and 6 months after CT. RESULTS: Mean baseline NT-proBNP concentration was 117.7 +/- 46.4 ng/L (slightly elevated in 3 patients). After first and last CT, NT-proBNP elevations to 299.7 +/- 176.2 ng/L and 287.1 +/- 147.4 ng/L were observed, respectively. Six months after CT, mean NT-proBNP concentration was 362.5 +/- 304.9 ng/L (elevated in 16 patients). Changes in NT-proBNP were significant in comparison with the baseline values (p < 0.001). Six months after CT, two patients with marked NT-proBNP elevations during CT developed treatment-related cardiomyopathy with symptoms of heart failure. NT-proBNP correlated with systolic and diastolic LV dysfunction on echocardiography (r = 0.514; p < 0.01) and (r = 0.587; p < 0.01). CTnT concentrations were negative (bellow 0.01 microg/L) during CT in all patients. Six months after CT, delayed cTnT positivity occurred in 3 patients. CK-MB mass remained within the reference range in all patients. CONCLUSION: Our study shows that anthracycline treatment is associated with acute and chronic neurohumoral activation of cardiac dysfunction that is manifested by a significant increase in NT-proBNP. It seems that NT-proBNP could be useful in the early detection of anthracycline cardiotoxicity. CTnT negativity during anthracycline treatment suggests that anthracyclines, even in higher cumulative doses, do not cause detectable acute injury to cardiomyocyte structure. Further studies using more sensitive markers of cardiac damage will be needed in this context.
J M Horacek; R Pudil; L Jebavy; M Tichy; P Zak; J Maly
Related Documents :
9832489 - Diagnostic value of plasma levels of brain natriuretic peptide in arrhythmogenic right ...
7221189 - Significant increase of plasma prostaglandins in cancer patients.
21072029 - The role of b-type natriuretic peptide testing in patients with acute coronary syndromes.
20078209 - Compatibility and stability of ternary admixtures of tramadol, haloperidol, and hyoscin...
18199989 - Assessment of anthracycline-induced cardiotoxicity with biochemical markers.
8357099 - Increased plasma endothelin levels in kawasaki disease: a possible marker for kawasaki ...
21039889 - Evaluation of oxidative stress and antioxidant profile in patients with oral lichen pla...
22323779 - Subregional patterns of preferential striatal dopamine transporter loss differ in parki...
15936489 - Doppler sonography in assessing disease activity in rheumatoid arthritis.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Experimental oncology     Volume:  29     ISSN:  1812-9269     ISO Abbreviation:  Exp. Oncol.     Publication Date:  2007 Dec 
Date Detail:
Created Date:  2008-01-17     Completed Date:  2008-04-08     Revised Date:  2010-01-15    
Medline Journal Info:
Nlm Unique ID:  101230541     Medline TA:  Exp Oncol     Country:  Ukraine    
Other Details:
Languages:  eng     Pagination:  309-13     Citation Subset:  IM    
2nd Department of Medicine - Clinical Hematology, University Hospital and Charles University, Faculty of Medicine in Hradec Kralove, Czech Republic.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Disease
Anthracyclines / adverse effects*
Biological Markers / blood*
Creatine Kinase, MB Form / blood
Heart Diseases / blood*,  chemically induced*
Leukemia / drug therapy
Middle Aged
Natriuretic Peptide, Brain / blood*
Peptide Fragments / blood*
Sensitivity and Specificity
Troponin T / blood
Reg. No./Substance:
0/Anthracyclines; 0/Biological Markers; 0/Peptide Fragments; 0/Troponin T; 0/pro-brain natriuretic peptide (1-76); 114471-18-0/Natriuretic Peptide, Brain; EC Kinase, MB Form

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Clinical and histopathological features of the oral mucosa in allogeneic haematopoietic stem cell tr...
Next Document:  Differential expression of 16 genes coding for cell cycle- and apoptosis-related proteins in vitamin...